Q3 Earnings Estimate for Genmab A/S Issued By William Blair

Genmab A/S (NASDAQ:GMAB - Free Report) - Investment analysts at William Blair issued their Q3 2025 earnings per share estimates for Genmab A/S in a note issued to investors on Thursday, February 13th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of $0.46 for the quarter. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S's Q4 2025 earnings at $0.44 EPS and FY2028 earnings at $4.02 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Several other research firms have also issued reports on GMAB. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Finally, BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Genmab A/S presently has an average rating of "Moderate Buy" and a consensus price target of $42.17.

Genmab A/S Trading Up 2.1 %

Shares of NASDAQ:GMAB traded up $0.47 during trading on Monday, hitting $22.44. 1,030,388 shares of the company were exchanged, compared to its average volume of 1,581,457. The stock has a market cap of $14.85 billion, a price-to-earnings ratio of 12.90, a P/E/G ratio of 2.57 and a beta of 0.96. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The firm has a fifty day moving average price of $20.64 and a two-hundred day moving average price of $22.97.

Hedge Funds Weigh In On Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Legacy Wealth Asset Management LLC raised its holdings in Genmab A/S by 1.1% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company's stock valued at $1,097,000 after acquiring an additional 471 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after purchasing an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its holdings in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.